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We believe COVID-19 was first identified in 
Wuhan, China, in December 20191-3. By 19 July 
2020 there were already 14.349 million cases 
and over 603,000 deaths worldwide giving a case 
fatality ratio among confirmed cases of 4.21%4. This 
includes Bangladesh with 204,525 confirmed cases 
by 19 July and 2618 deaths; however, recognising 
appreciable underreporting3-5. Since COVID-19 is 
principally spread through droplet infection and 
physical contact6,with an appreciable number of 
patients asymptomatic and currently no vaccine, 
current prevention strategies have centred on active 
testing, lockdown, closure of borders coupled with 
quarantining, sanitisation and social distancing6-12. 
However, the rate of adoption of preventative measures 
has varied considerably across countries,exacerbated 
by lack of testing facilities, clean water/ sanitisation 
and economic concerns, affecting prevalence and 
mortality rates5,13,14. Vietnam is an example of a 
developing country that rapidly introduced a range 
of measures under the banner ‘Fighting the epidemic 
is like fighting against the enemy’, which combined 
with other factors have resulted in only 383 reported 
cases up to 19 July and no deaths4,15-17. Rapid 
initiatives among a number of African countries 
including Botswana and Namibia have also limited 
prevalence and mortality rates in these countries13. 
This is despite concerns that patients of Black Afro-
Caribbean and South Asian origin with COVID-19 in 
the United Kingdom appear at appreciably increased 
risk of dying from COVID-19 versus those of white 
ethnicity18-22. The lack of intensive care beds and 
ventilatory support has also been a concern among 
developing countries during the pandemic potentially 
adversely affecting mortality rates5,13; however, we 
are seeing shortages of ventilators being addressed 
through local innovations13.
A number of medicines have been proposed for 
managing patients with COVID-1923,24. However, 
to date, there appears to be no cure although 
dexamethasone and remdesivir are showing promise 
in well constructed studies5,25-27. Initially, there was 
considerable hype surrounding the use of chloroquine 
and hydroxychloroquine with or without antibiotics 
such as azithromycin5,28-30 despite concerns with the 
lack of control arms in the initial studies31. The hype 
resulted in appreciable increases in the utilisation and 
prices of antimalarials as well as suicides across a 
number of countries, enhanced by endorsement from 
Governments and Medical Societies5,32-35.However, 
more recent studies, including randomised clinical 
trials, failed to show any benefit alongside potential 
harm36-40. As a result, the World Health Organisation 
(WHO) and the National Institute of Health in the US 
have stopped the hydroxychloroquine arm in their 
studies, with Governments, Societies and Agencies 
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now also advising caution41-45. Hydroxychloroquine 
is still endorsed though in India for prophylaxis 
following the study of Chatterjee et al. (2020) despite 
concerns46,47. 
Recommendations of unproven or ineffective 
medicines are a concern in countries where there are 
high levels of co-payment, and where the costs of 
providing treatment for family members can have 
catastrophic consequences as seen for instance in 
Bangladesh and Pakistan5,48,49. Funding for unproven 
treatments, especially where there are increasing 
prices due to shortages, can divert valuable resources 
away from treating other priority infectious diseases 
as well as non-communicable diseases (NCDs) such 
as coronary vascular disease (CVD) and diabetes, 
which are on the increase across countries5,50,51. 
Instigating an evidence-based philosophy among 
all key stakeholder groups including physicians and 
pharmacists, starting in university and continuing, can 
help improve the situation in the future13,52. We have 
seen this philosophy work in practice in Stockholm, 
Sweden, where there are high adherence rates among 
prescribing physicians to a list of just 200 medicines 
in ambulatory care (the ‘Wise List’) covering over 
95% of the needs of patients. High adherence rates 
have been achieved through instigating robust 
evidence-based systems for reviewing medicines for 
incorporating into the list including strong conflict-
of-interest statements. Alongside this, actively 
broadcasting the List through multiple channels 
including making a patient version available, 
physicians able to robustly question those compiling 
the list as well as continual monitoring of physician 
prescribing against the recommendations with 
feedback on a monthly basis53,54. Robust evidence-
based approaches have enhanced physician trust 
in the recommendations, which is reflected in high 
adherence rates55. Some countries have also started 
fines for instigating companies and individuals 
broadcasting misinformation during the pandemic, 
providing direction to others13. Patient organisations 
can also play a role addressing misinformation 
regarding prevention and management of COVID-19 
through social media and other approaches13, with 
evidence showing that patients do take on board key 
messages during the pandemic56.
Inappropriate prescribing of antimicrobials will 
also increase resistance rates alongside costs to 
governments, health authorities and patients, which 
is a key concern across all countries57-59. Community 
pharmacists and others can play a key role in 
reducing inappropriate prescribing and dispensing 
of antimicrobials, enhanced through educational 
input to address any information gaps in their 
knowledge57,60-62. Patient education will also typically 
be needed to reduce requests for antimicrobials 
especially in countries with high levels of self-
purchasing57.  
There are also concerns with the level of stigma 
associated with those who manage patients with 
COVID-19 along with those with the virus63-65. 
Alongside this, a potential increase in mental health 
disorders as a result of lockdown measures, fears 
about morbidity and mortality with COVID-19 as well 
as adverse reactions from potential treatments13,66. 
During pandemics, community pharmacists 
and others can help with educational and other 
approaches including increased use of telemedicine 
to address any stigma and mental health issues 
associated with the virus67,68.Community pharmacists 
can also help address other unintended consequences 
from the pandemic. These include concerns with 
reduced immunisation, patients unable to obtain 
their medicines for priority diseases including 
NCDs, as well as patients with NCDs not adhering 
to their medicines, alongside communicating with 
patients on ways to reduce the spread of the virus69-72. 
Addressing concerns with availability and adherence 
to medicines is especially important in patients 
with NCDs such as CVD and diabetes during the 
pandemic as highlighted by the WHO and others73,74. 
Encouragingly there has been increase in the 
utilisation of personal protective equipment (PPE) 
across countries to help prevent the spread of 
COVID-19; however this has resulted in shortages 
and associated price rises5,13,75. Shortages are though 
being addressed through increasing local production 
in a number of countries, and this is likely to 
remain13,76. However care is needed to address 
concernswith sub-standard or falsified medicines, 
which are likely to increase where there are medicine 
shortages13,77. Initiatives such as the Lomé initiative, 
which places falsified and substandard medicines 
on the highest political agenda, alongside current 
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measures to strengthen the legal response to falsified 
medicines, are considerations for the future in 
pertinent developing countries78. 
In conclusion, COVID-19 has had, and continues to 
have, a devastating effect across countries. Its health 
impact can be minimised by rapid instigation of 
preventative measures. However, there needs to be 
plans in place to reduce the unintended consequences 
of lockdown measures, which can be significant. 
Governments and healthcare professionals also need 
to be proactive to reduce the spread of misinformation 
and any hype surrounding unproven treatments as 
this can also be catastrophic for families especially 
in developing countries with high co-payment levels. 
Finally, the economic and health consequences of 
preventative strategies also need to be considered 
alongside the gains since their overall impact could 
be greater than the morbidity and mortality associated 
with COVID-19 in the first place.This is especially 
important for COVID-19 in countries with younger 
populations, and where an appreciable number of 
citizens rely on daily work for their survival. We will 
continue to monitor the unintended consequences 
across countries to provide future direction.
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